Marksans Pharma Ltd. Share Price & Stock Analysis

Marksans Pharma Ltd. (NSE: MARKSANS, BSE: 524404) is a Mumbai, Maharashtra-based company in the Pharmaceuticals industry. With a market capitalisation of ₹13,892 Cr, it ranks #485 by market cap among the 6,197 Indian listed companies on FinBizNet, and #11 of 63 in Pharmaceuticals. At ₹316.80 (as of 16 Nov 2026), the share price is 9.7% below its 52-week high of ₹350.95 and 104.4% above its 52-week low of ₹155.00. The share price is up 74.1% over one year and up 5.0% over three months.

Key Metrics

Current Price₹316.80
Market Cap₹13,892 Cr
NSE SymbolMARKSANS
BSE Code524404
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals
Sub-IndustryBiotechnology and Life Sciences > Pharmaceuticals
P/E Ratio35
Return on Equity25.45%
Return on Assets8.85%
52-Week Range₹155.00 – ₹350.95
1-Year Price Change+74.1%
3-Month Price Change+5.0%
Beta (1Y)0.69
Dividend Yield0.28%
HeadquartersMumbai, Maharashtra
Websitemarksanspharma.com

Latest Quarterly Results — Q2 FY27

Revenue₹940 Cr
Net Profit₹144 Cr
Net Margin15.3%
EPS (Basic)₹3.12
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Marksans Pharma Ltd. Quarterly Revenue and Profit Trend

Marksans Pharma Ltd. reported revenue of ₹940 Cr in Q2 FY27, up 30.5% from ₹720 Cr in Q2 FY26 and up 11.8% from ₹841 Cr in Q1 FY27. It posted a net profit of ₹144 Cr for the quarter, against a net profit of ₹99 Cr in Q2 FY26 (up 44.8%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹71 Cr (Q4 FY25) to ₹940 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹940 Cr₹144 Cr15.3%
Q1 FY27₹841 Cr₹159 Cr19.0%
Q4 FY26₹856 Cr₹149 Cr17.4%
Q3 FY26₹754 Cr₹114 Cr15.1%
Q2 FY26₹720 Cr₹99 Cr13.8%
Q1 FY26₹620 Cr₹58 Cr9.4%
Q4 FY25₹71 Cr₹9 Cr12.8%

Consolidated figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 43.87% of Marksans Pharma Ltd.'s shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 44.7% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About Marksans Pharma Ltd.

Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. Its product portfolio includes plain, enteric-coated, and film coated tablets; soft gelatin and hard capsules; oral liquids; and ointments, as well as creams and liquids. The company provides its products to supermarkets, high street retailers, pharmacy chains, and wholesalers. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.

Products and Services

1. Bulk Drugs Division-This segment engages in manufacturing pharmaceutical formulations. 2. Formulations Division-This segment engages in the manufacture and sale of bulk drugs. 3. Research, Manufacturing and Marketing of Pharmaceutical Formulation-This segment engages in the manufacture and sale of formulations and active pharmaceutical ingredients.

Business Segments

1. Pharmaceuticals-100%

Marksans Pharma Ltd. vs Peers — Pharmaceuticals

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Abbott India Ltd.₹56,531 Cr36.334.46%₹1,814 Cr-8.1%
Emcure Pharmaceuticals Ltd₹42,344 Cr47.919.57%₹2,820 Cr+73.3%
Ajanta Pharma Limited₹41,474 Cr39.425.39%₹1,794 Cr+27.8%
Piramal Pharma Ltd₹32,600 Crn/m-4.00%₹2,617 Cr+22.8%
RUBICON RESEARCH LIMITED₹28,526 Cr112.319.14%₹576 Cr+162.7%
Caplin Point Laboratories Ltdte₹18,155 Cr28.319.94%₹630 Cr+23.6%
Pfizer Ltd.₹17,811 Cr24.517.16%₹727 Cr-24.2%
Eris Lifesciences Ltd₹17,691 Cr28.318.07%₹892 Cr-17.5%
Marksans Pharma Ltd.₹13,892 Cr3525.45%₹940 Cr+74.1%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Marksans Pharma Ltd.?

Marksans Pharma Ltd. is trading at ₹316.80, with a market capitalisation of ₹13,892 Cr.

Which sector does Marksans Pharma Ltd. belong to?

Marksans Pharma Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).

What are the key financial ratios of Marksans Pharma Ltd.?

Marksans Pharma Ltd. has a P/E of 35 and a return on equity of 25.45%.

What is the stock symbol of Marksans Pharma Ltd.?

Marksans Pharma Ltd. is listed on the NSE under the symbol MARKSANS and on the BSE under the scrip code 524404.

How has Marksans Pharma Ltd.'s share price moved over the past year?

Marksans Pharma Ltd.'s share price is up 74.1% over one year and up 5.0% over three months. Its 52-week range is ₹155.00 to ₹350.95.

What were Marksans Pharma Ltd.'s latest quarterly results?

In Q2 FY27, Marksans Pharma Ltd. reported revenue of ₹940 Cr and net profit of ₹144 Cr, with basic EPS of ₹3.12 (consolidated, parsed from the company's exchange filing).

How have Marksans Pharma Ltd.'s revenue and profit changed over the past year?

Marksans Pharma Ltd. reported revenue of ₹940 Cr in Q2 FY27, up 30.5% from ₹720 Cr in Q2 FY26 and up 11.8% from ₹841 Cr in Q1 FY27.

What is the promoter holding in Marksans Pharma Ltd.?

Promoters held 43.87% of Marksans Pharma Ltd.'s shares as of Sept 2026, unchanged from Sept 2025.

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.